Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Mark Alles
Age : 61
Public asset : 1,224,933 USD
Country of residence : Unknown
Linked companies : Turning Point Therapeutics, Inc. - Antengene Corporation Limited - Syros Pharmaceuticals, Inc. - Juno Therapeutics Inc

Biography of Mark Alles 
Mark J. Alles is on the board of Syros Pharmaceuticals, Inc., Juno Therapeutics, Inc., Antengene Corporation Co., Ltd. and Antengene Corp. Ltd. In the past he was Chairman, President, CEO & COO at Celgene Corp., Principal at Centocor, Inc., Principal at Bayer Corp. and Vice President-Oncology Business Unit at Aventis Pharmaceuticals, Inc. Mr. Alles received an undergraduate degree from Lock Haven University of Pennsylvania.


Current positions of Mark Alles 
Holdings of Mark Alles 
Mark Alles : Personal Network 
Most Read News 
10/15JACK DORSEY : Square CEO Dorsey says looking to build a bitcoin mining system - tweet
RE
10/12CATHIE WOOD : ARK Invest's Wood warns upcoming economic downturn in China 'obvious'
RE
10/11JAMIE DIMON : JPMorgan's Dimon blasts bitcoin as 'worthless', due for regulation
RE
10/17ELON MUSK : Tesla's Musk dials into Volkswagen executive conference
RE
10/13WARREN BUFFETT : Buffett-backed Nubank turns a profit in Brazil
RE
10/18MATTHEW MOULDING : THG's Moulding gives up 'golden share' after stock tumbles
RE
10/12JACK MA : Billionaire Alibaba founder Jack Ma reappears in Hong Kong - sources
RE
10/09ELON MUSK : First Berlin Teslas could come next month, Musk tells fans
RE
10/18BILL GATES : Electric vehicle battery startup ONE backed by BMW, Gates-led firm
RE
10/06CARL ICAHN : Stock Futures Point to Fresh Selloff on Wall Street
DJ
More news


© 2021 People and Ownership :   
Mark Alles : Connections 


Latest news about Mark Alles 
05/25TURNING POINT THERAPEUTICS : Names Former Celgene CEO as Board Chair
MT
05/25Turning Point Therapeutics, Inc. Announces Board Changes
CI
2019Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal
RE
2019Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
RE
2019Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
RE
More news